Immune thrombocytopenia in two infant cases managed with eltrombopag

Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2‐month‐old infant

“…18 Thus, this is the youngest reported case to receive TPO-RA with a good response. Our report, in addition to the previous reports, 18,19 showed that early treatment with TPO-RAs may be a treatment option in early infants with newly diagnosed and refractory ITP to avoid the side effects associated with long-term corticosteroid use. It should be noted that the adverse effects of long-term use of TPO-RA in young infants, such as myelofibrosis, thrombosis, and neurocognitive dysfunction, have not yet been determined.…”

“…5 months of age and received eltrombopag 12 and 3 weeks after diagnosis, respectively. 18 Thus, this is the youngest reported case to receive TPO-RA with a good response. Our report, in addition to the previous reports, 18,19 showed that early treatment with TPO-RAs may be a treatment option in early infants with newly diagnosed and refractory ITP to avoid the side effects associated with long-term corticosteroid use.…”

“…However, data on TPO-RA use for ITP in infants are limited. [17][18][19] Herein, we report a case of a 2-month-old male with newly diagnosed and refractory ITP who responded well to romiplostim, a TPO-RA. Informed consent was obtained from the patient's parents.…”